OCUL
Ocular Therapeutix, Inc. [OCUL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OCUL Stock Summary
Top 10 Correlated Stocks
OCUL
In the News
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:
Ocular Therapeutix, Inc. (OCUL) Q3 2023 Earnings Call Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President and CEO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Peter Kaiser - Chief Medical Advisor, Retina Conference Call Participants Jon Wolleben - JMP Yi Chen - H.C. Wainwright Operator Good day.
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023 at 11:00 AM EDT.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.28 per share a year ago.
Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that 12-month data from the U.S.-based Phase 1 trial evaluating OTX-TKI for the treatment of wet AMD will be presented at the 2023 Clinical Trials at the Summit Annual Meeting being held on June 10th in Park City, Utah. The Company will also participate in a panel discussing the challenges of bringing novel treatments to the market. Ocular Therapeutix is also sponsoring a presentation discussing the Company's proprietary bioresorbable hydrogel-based formulation technology and retina focused clinical programs. A conference call discussing the 12-month data from the U.S.-based Phase 1 clinical trial of OTX-TKI presented at the Clinical Trials at the Summit will be hosted by the Ocular Therapeutix management team on Monday, June 12th at 8:30 AM ET.
Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 12:30 PM EDT at the Marriott Marquis in New York, NY.
Ocular Therapeutix, Inc. (OCUL) Q1 2023 Earnings Call Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Rabia Ozden - Chief Medical Officer Steve Meyers - Senior Vice President of Commercial Conference Call Participants Jon Wolleben - JMP Securities Joe Catanzaro - Piper Sandler Tara Bancroft - Cowen Colleen Kusy - Baird Yi Chen - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by.
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.
Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY.
OCUL Financial details
OCUL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0.09 | 0.29 | 0.57 | 0.67 | |
| Net income per share | -1.51 | -1.99 | -2.63 | -0.14 | -0.83 | |
| Operating cash flow per share | -1.29 | -1.71 | -0.88 | -0.86 | -0.78 | |
| Free cash flow per share | -1.34 | -1.76 | -0.9 | -0.87 | -0.82 | |
| Cash per share | 1.42 | 1.2 | 3.75 | 2.15 | 1.33 | |
| Book value per share | 0.94 | -0.08 | 1.25 | 1.15 | 0.46 | |
| Tangible book value per share | 0.94 | -0.08 | 1.25 | 1.15 | 0.46 | |
| Share holders equity per share | 0.94 | -0.08 | 1.25 | 1.15 | 0.46 | |
| Interest debt per share | 0.7 | 1.45 | 1.07 | 0.86 | 0.93 | |
| Market cap | 151.7M | 178.83M | 1.26B | 532.46M | 216.02M | |
| Enterprise value | 122.42M | 183.74M | 1.09B | 427.28M | 178M | |
| P/E ratio | -2.63 | -1.99 | -7.88 | -49.28 | -3.41 | |
| Price to sales ratio | 76.23 | 42.31 | 72.26 | 12.23 | 4.2 | |
| POCF ratio | -3.08 | -2.31 | -23.48 | -8.12 | -3.62 | |
| PFCF ratio | -2.97 | -2.24 | -23.12 | -7.98 | -3.41 | |
| P/B Ratio | 4.23 | -49.26 | 16.53 | 6.05 | 6.11 | |
| PTB ratio | 4.23 | -49.26 | 16.53 | 6.05 | 6.11 | |
| EV to sales | 61.52 | 43.47 | 62.52 | 9.82 | 3.46 | |
| Enterprise value over EBITDA | -2.1 | -2.17 | -17.36 | -5.48 | -2.29 | |
| EV to operating cash flow | -2.49 | -2.37 | -20.32 | -6.52 | -2.99 | |
| EV to free cash flow | -2.4 | -2.3 | -20 | -6.4 | -2.81 | |
| Earnings yield | -0.38 | -0.5 | -0.13 | -0.02 | -0.29 | |
| Free cash flow yield | -0.34 | -0.45 | -0.04 | -0.13 | -0.29 | |
| Debt to equity | 0.69 | -16.35 | 0.77 | 0.67 | 1.82 | |
| Debt to assets | 0.34 | 0.75 | 0.22 | 0.29 | 0.43 | |
| Net debt to EBITDA | 0.5 | -0.06 | 2.71 | 1.35 | 0.49 | |
| Current ratio | 6.14 | 5 | 9.23 | 7.26 | 4.13 | |
| Interest coverage | -34 | -14.06 | -9.29 | -11.7 | -11.2 | |
| Income quality | 0.82 | 0.9 | 0.34 | 10 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.01 | 0 | 0 | -0.07 | 0 | |
| Sales general and administrative to revenue | 9.44 | 5.23 | 1.31 | 0.73 | 0.63 | |
| Research and developement to revenue | 18.55 | 9.72 | 1.65 | 1.15 | 1.04 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0.03 | 0.02 | 0.02 | 0.06 | |
| Capex to revenue | -0.95 | -0.53 | -0.05 | -0.03 | -0.07 | |
| Capex to depreciation | -0.83 | -0.88 | -0.3 | -0.49 | -1.76 | |
| Stock based compensation to revenue | 3.76 | 2.07 | 0.43 | 0.34 | 0.33 | |
| Graham number | 5.66 | 1.89 | 8.61 | 1.91 | 2.92 | |
| ROIC | -0.94 | -1.36 | -0.45 | -0.83 | -0.64 | |
| Return on tangible assets | -0.79 | -1.14 | -0.61 | -0.05 | -0.42 | |
| Graham Net | 0.45 | -0.56 | 0.86 | 0.83 | 0.07 | |
| Working capital | 47.03M | 48.14M | 219.5M | 164.96M | 98.23M | |
| Tangible asset value | 35.88M | -3.63M | 76.1M | 88M | 35.38M | |
| Net current asset value | 19.03M | -22.2M | 60.39M | 74.41M | 15.72M | |
| Invested capital | 0.69 | -16.35 | 0.77 | 0.67 | 1.82 | |
| Average receivables | 213.5K | 1.37M | 7.4M | 16.69M | 21.23M | |
| Average payables | 3.27M | 3.12M | 2.99M | 3.65M | 4.86M | |
| Average inventory | 169.5K | 585.5K | 1.08M | 1.23M | 1.61M | |
| Days sales outstanding | 36.87 | 220.02 | 256.97 | 177.25 | 151.16 | |
| Days payables outstanding | 2.33K | 513.04 | 474.69 | 380.41 | 411.87 | |
| Days of inventory on hand | 170.33 | 149.77 | 210.45 | 103.55 | 158.7 | |
| Receivables turnover | 9.9 | 1.66 | 1.42 | 2.06 | 2.41 | |
| Payables turnover | 0.16 | 0.71 | 0.77 | 0.96 | 0.89 | |
| Inventory turnover | 2.14 | 2.44 | 1.73 | 3.52 | 2.3 | |
| ROE | -1.61 | 24.78 | -2.1 | -0.12 | -1.79 | |
| Capex per share | -0.05 | -0.05 | -0.01 | -0.02 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.16 | 0.18 | 0.17 | 0.19 | 0.19 | |
| Net income per share | -0.35 | -0.15 | -0.47 | -0.26 | -0.01 | |
| Operating cash flow per share | -0.17 | -0.22 | -0.26 | -0.26 | -0.1 | |
| Free cash flow per share | -0.18 | -0.25 | -0.3 | -0.28 | -0.1 | |
| Cash per share | 1.57 | 1.33 | 1.02 | 0.85 | 1.39 | |
| Book value per share | 0.6 | 0.46 | 0.13 | 0.04 | 0.1 | |
| Tangible book value per share | 0.6 | 0.46 | 0.13 | 0.04 | 0.1 | |
| Share holders equity per share | 0.6 | 0.46 | 0.13 | 0.04 | 0.1 | |
| Interest debt per share | 0.8 | 0.86 | 0.86 | 0.86 | 1 | |
| Market cap | 319.45M | 216.4M | 407.83M | 402.73M | 249.23M | |
| Enterprise value | 258.2M | 178.38M | 393.41M | 400.89M | 221.7M | |
| P/E ratio | -2.98 | -4.61 | -2.8 | -4.87 | -120.75 | |
| Price to sales ratio | 26.7 | 15.37 | 30.49 | 26.52 | 16.67 | |
| POCF ratio | -24.26 | -12.76 | -20.42 | -20.06 | -32.23 | |
| PFCF ratio | -22.88 | -11.33 | -17.46 | -18.25 | -31.19 | |
| P/B Ratio | 6.91 | 6.12 | 42 | 130.46 | 31.74 | |
| PTB ratio | 6.91 | 6.12 | 42 | 130.46 | 31.74 | |
| EV to sales | 21.58 | 12.67 | 29.42 | 26.4 | 14.83 | |
| Enterprise value over EBITDA | -12.44 | -9.42 | -17.89 | -20.91 | -11.54 | |
| EV to operating cash flow | -19.61 | -10.52 | -19.7 | -19.97 | -28.67 | |
| EV to free cash flow | -18.49 | -9.34 | -16.85 | -18.17 | -27.74 | |
| Earnings yield | -0.08 | -0.05 | -0.09 | -0.05 | 0 | |
| Free cash flow yield | -0.04 | -0.09 | -0.06 | -0.05 | -0.03 | |
| Debt to equity | 1.29 | 1.82 | 6.65 | 20.98 | 10.57 | |
| Debt to assets | 0.38 | 0.43 | 0.5 | 0.53 | 0.51 | |
| Net debt to EBITDA | 2.95 | 2.01 | 0.66 | 0.1 | 1.43 | |
| Current ratio | 4.98 | 4.13 | 3.61 | 3.11 | 4.03 | |
| Interest coverage | -11.99 | -10.48 | -12.75 | -10.33 | 5.61 | |
| Income quality | 0.54 | 1.09 | 0.66 | 0.97 | 14.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.71 | 0.59 | 0.68 | 0.54 | 0.57 | |
| Research and developement to revenue | 1.15 | 0.96 | 1.1 | 0.99 | 1 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.06 | 0.13 | 0.17 | 0.1 | 0.03 | |
| Capex to revenue | -0.07 | -0.15 | -0.25 | -0.13 | -0.02 | |
| Capex to depreciation | -1.56 | -4.38 | -7 | -3.05 | -0.29 | |
| Stock based compensation to revenue | 0.35 | 0.3 | 0.34 | 0.29 | 0.3 | |
| Graham number | 2.17 | 1.25 | 1.15 | 0.49 | 0.12 | |
| ROIC | -0.21 | -0.13 | -0.32 | -0.29 | 0.14 | |
| Return on tangible assets | -0.17 | -0.08 | -0.28 | -0.17 | 0 | |
| Graham Net | 0.31 | 0.07 | -0.3 | -0.4 | -0.32 | |
| Working capital | 116.35M | 98.23M | 77.45M | 68.36M | 106.19M | |
| Tangible asset value | 46.23M | 35.38M | 9.71M | 3.09M | 7.85M | |
| Net current asset value | 33.27M | 15.72M | -11.7M | -18.76M | -13.27M | |
| Invested capital | 1.29 | 1.82 | 6.65 | 20.98 | 10.57 | |
| Average receivables | 20.14M | 20.56M | 21.22M | 24.22M | 25.45M | |
| Average payables | 4.51M | 5.22M | 5.28M | 4.51M | 3.78M | |
| Average inventory | 1.52M | 1.76M | 2.12M | 2.24M | 2.23M | |
| Days sales outstanding | 148.95 | 136.35 | 142.15 | 161.85 | 142.01 | |
| Days payables outstanding | 445.22 | 455.15 | 403.37 | 246.53 | 260.39 | |
| Days of inventory on hand | 129.59 | 175.38 | 167.99 | 152.12 | 147.52 | |
| Receivables turnover | 0.6 | 0.66 | 0.63 | 0.56 | 0.63 | |
| Payables turnover | 0.2 | 0.2 | 0.22 | 0.37 | 0.35 | |
| Inventory turnover | 0.69 | 0.51 | 0.54 | 0.59 | 0.61 | |
| ROE | -0.58 | -0.33 | -3.75 | -6.7 | -0.07 | |
| Capex per share | -0.01 | -0.03 | -0.04 | -0.03 | 0 |
OCUL Frequently Asked Questions
What is Ocular Therapeutix, Inc. stock symbol ?
Ocular Therapeutix, Inc. is a US stock , located in Bedford of Ma and trading under the symbol OCUL
Is Ocular Therapeutix, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $10. The lowest prediction is $10 and the highest is $10
What is OCUL stock prediction ?
What is Ocular Therapeutix, Inc. stock quote today ?
Ocular Therapeutix, Inc. stock price is $2.575 today.
Is Ocular Therapeutix, Inc. stock public?
Yes, Ocular Therapeutix, Inc. is a publicly traded company.
Company Profile
- Volume Average 785.03K
- Market Capitalization 177.9M
- Employee 274
- CEO Mr. Antony Mattessich
- Headquarters Bedford,MA,US
- IPO Date 2014-07-25
-
Website
https://www.ocutx.com 
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
